Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer

107

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC). In July 2018, the company entered a Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to fund a research study entitled, “A Novel Therapeuti http://www.businesswire.com/news/home/20190701005143/en/Genprex-Update-Development-Oncoprex-Immunogene-Therapy-Combination/?feedref=JjAwJuNHiystnCoBq_hl-c_SXB-bY2T43rxUBWxEIvSqcp-o_pnudlUwsb5apQ1S4gUE65BTfjH3-pSuqdv0gW3cb3F4oTIgUqCPafFkgu61_izUl0FZkbDFZ7ZhSEmC